Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Pot

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|February 14, 2024
Complement Activation Is Associated With Disease Severity in Multiple SclerosisJohanna Oechtering, Kerstin Stein, Sabine A Schaedelin, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 28, 2023
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis PatientsAlexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Neurology(R) Neuroimmunology & Neuroinflammation|February 14, 2024
Complement Activation Is Associated With Disease Severity in Multiple SclerosisJohanna Oechtering, Kerstin Stein, Sabine A Schaedelin, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 28, 2023
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis PatientsAlexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Pageof 11